Integrative Sequencing in Germline and Hereditary Tumours
common.study.values.description
“Integrative Sequencing In Germline and Hereditary Tumours”
This study will investigate the utility of integrative sequencing of individuals and families at risk of hereditary cancer syndromes and will uncover novel contributors to tumourigenesis. Integrative sequencing refers to: 1. Whole genome sequencing (WGS) of the germline (inherited) genome 2. Whole exome sequencing (WES) or targeted/panel sequencing of tumour(s) (somatic, tumour-specific mutations) 3. DNA methylation (methylome) analysis of tumour(s) 4. RNA sequencing (transcriptome) of tumour(s) Eligible patients receiving genetic care at Princess Margaret Cancer Centre and the University Health Network may be approached by their genetic counsellor for participation in this study.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-no
common.study.methods.is-healthy-yes
common.study.methods.no-methods
participant.views.study.view.additional
participant.views.study.view.scientific-title
Integrative Sequencing In Germline and Hereditary Tumours
common.study.values.clinical-trial-id
NCT03857594
participant.views.study.view.id
aOYXBd
